COMPASS Pathways Receives FDA Approval for Psilocybin Trial

"We are excited to be starting this landmark trial which has the potential to transform lives. Depression is the leading cause of ill-health and disability worldwide, and treatment-resistant depression affects more than 100 million people," George Goldsmith, Chairman and Co-founder of COMPASS Pathways, said. "It is a huge unmet need and the trial will teach us more about how this new approach might address it."

"The design of this study has been a truly collaborative effort, with scientists, clinicians, patient representatives and regulators from Europe and North America working together with the goal of helping patients suffering with treatment-resistant depression," Ekaterina Malievskaia, Chief Medical Officer and Co-founder of COMPASS, said.

--------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.